MY ACCOUNT | NEWSLETTER |

Walgreens Boots Alliance reports Fiscal 2023 second quarter results


Walgreens Boots Alliance announced financial results for the second quarter of the fiscal year on March 28, confirming full-year guidance despite a decline in earnings per share (EPS) and sales. Sales for the quarter increased 3.3% year over year to $34.9 billion, but adjusted EPS decreased 27.2% to $1.16, reflecting a 26% inverse trend due to the decline in COVID-19 vaccine and testing volumes. 

According to a news release, Walgreens Boots Alliance has invested $3.5 billion in VillageMD's acquisition of Summit Health to accelerate U.S. health care segment sales and improve profitability. The company also partially sold its stakes in AmerisourceBergen and Option Care Health for $1.5 billion in after-tax proceeds.

Investments in the healthcare segment and acquisitions

The company is maintaining its adjusted full-year earnings guidance of $4.45 to $4.65 as strong growth in the core business which is more than offset by the lag compared with peak COVID-19 demand for testing and vaccines, according to the news release. 

The company closed VillageMD's acquisition of Summit Health and signed on to Horizon Blue Cross Blue Shield of New Jersey as the fourth payor partner for Walgreens Health. As mentioned above, the company also sold its stakes in AmerisourceBergen and Option Care Health to optimize its capital allocation.

Consumer-centric healthcare

Walgreens Boots Alliance continues to transform and align its core business, addressing industry-wide pharmacist labor shortages and maintaining a leading role in COVID-19 vaccinations and testing. The company is also building its next growth engine with consumer-centric healthcare solutions and focusing its portfolio to optimize capital allocation. In addition, the company named new senior vice presidents and directors for pharmacy and retail, and launched its fiscal 2022 Environmental, Social and Governance Report.

Solid second quarter with an acceleration in February

CEO Rosalind Brewer said in the news release that the company "exited a solid second quarter with acceleration in February, adding to our confidence in driving strong growth in the second half of the year. With the closing of VillageMD's acquisition of Summit Health, WBA is now one of the largest players in primary care, with best-in-class assets across the care continuum. Both Walgreens and Boots are performing well by delivering compelling value to consumers, playing a critical role as community health destinations, and successfully navigating a challenging environment. We will continue to take bold actions to create sustainable long-term shareholder value."

Read more details in the company's news release: https://www.walgreensbootsalliance.com/news-media/press-releases/2023/walgreens-boots-alliance-reports-fiscal-2023-second-quarter-results

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats

Like0
Dislike0

Additive manufacturing to veterinary practice: Recovery of bony defects after the osteosarcoma resection in canines

Like0
Dislike0

Antimicrobial drug use in poultry

Like0
Dislike0

New hope and compassionate care for animal patients in pain

Like0
Dislike0

Neogen® Renews Official Sponsorship with US Equestrian to Continue Advancing Equine Health Education

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top